These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31855104)

  • 41. TCDD-inducible poly-ADP-ribose polymerase (TIPARP/PARP7) mono-ADP-ribosylates and co-activates liver X receptors.
    Bindesbøll C; Tan S; Bott D; Cho T; Tamblyn L; MacPherson L; Grønning-Wang L; Nebb HI; Matthews J
    Biochem J; 2016 Apr; 473(7):899-910. PubMed ID: 26814197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of Poly(ADP-Ribose) Polymerase Macrodomain Inhibitors Using an AlphaScreen Protocol.
    Ekblad T; Verheugd P; Lindgren AE; Nyman T; Elofsson M; Schüler H
    SLAS Discov; 2018 Apr; 23(4):353-362. PubMed ID: 29316839
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Are PARPs promiscuous?
    Feijs KLH; Žaja R
    Biosci Rep; 2022 May; 42(5):. PubMed ID: 35380161
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Double-Edged Sword: The Two Faces of PARylation.
    Kang M; Park S; Park SH; Lee HG; Park JH
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077221
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Poly-ADP ribosylation in DNA damage response and cancer therapy.
    Hou WH; Chen SH; Yu X
    Mutat Res Rev Mutat Res; 2019; 780():82-91. PubMed ID: 31395352
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PARG Inhibitors and Functional PARG Inhibition Models.
    Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M
    Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation.
    Gibson BA; Zhang Y; Jiang H; Hussey KM; Shrimp JH; Lin H; Schwede F; Yu Y; Kraus WL
    Science; 2016 Jul; 353(6294):45-50. PubMed ID: 27256882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Why structure and chain length matter: on the biological significance underlying the structural heterogeneity of poly(ADP-ribose).
    Reber JM; Mangerich A
    Nucleic Acids Res; 2021 Sep; 49(15):8432-8448. PubMed ID: 34302489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selective probing of ADP-ribosylation reactions with oxidized 2'-deoxy-nicotinamide adenine dinucleotide.
    Alvarez-Gonzalez R; Moss J; Niedergang C; Althaus FR
    Biochemistry; 1988 Jul; 27(14):5378-83. PubMed ID: 3139033
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase.
    Banasik M; Komura H; Shimoyama M; Ueda K
    J Biol Chem; 1992 Jan; 267(3):1569-75. PubMed ID: 1530940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SnapShot: ADP-Ribosylation Signaling.
    Hottiger MO
    Mol Cell; 2015 Jun; 58(6):1134-1134.e1. PubMed ID: 26091348
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging roles of eraser enzymes in the dynamic control of protein ADP-ribosylation.
    O'Sullivan J; Tedim Ferreira M; Gagné JP; Sharma AK; Hendzel MJ; Masson JY; Poirier GG
    Nat Commun; 2019 Mar; 10(1):1182. PubMed ID: 30862789
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ADP-Ribosylation in Antiviral Innate Immune Response.
    Du Q; Miao Y; He W; Zheng H
    Pathogens; 2023 Feb; 12(2):. PubMed ID: 36839575
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ART2, a T cell surface mono-ADP-ribosyltransferase, generates extracellular poly(ADP-ribose).
    Morrison AR; Moss J; Stevens LA; Evans JE; Farrell C; Merithew E; Lambright DG; Greiner DL; Mordes JP; Rossini AA; Bortell R
    J Biol Chem; 2006 Nov; 281(44):33363-72. PubMed ID: 16931513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identifying Direct Protein Targets of Poly-ADP-Ribose Polymerases (PARPs) Using Engineered PARP Variants-Orthogonal Nicotinamide Adenine Dinucleotide (NAD+) Analog Pairs.
    Carter-O'Connell I; Cohen MS
    Curr Protoc Chem Biol; 2015 Jun; 7(2):121-39. PubMed ID: 26344237
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A desthiobiotin labelled NAD
    Rieth S; Spliesgar D; Orth J; Lehner M; Kasprzyk R; Stengel F; Marx A
    Chembiochem; 2024 Mar; 25(5):e202300797. PubMed ID: 38236015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioorthogonally Functionalized NAD(+) Analogues for In-Cell Visualization of Poly(ADP-Ribose) Formation.
    Wallrodt S; Buntz A; Wang Y; Zumbusch A; Marx A
    Angew Chem Int Ed Engl; 2016 Jun; 55(27):7660-4. PubMed ID: 27080423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The PARP Way to Epigenetic Changes.
    Ummarino S; Hausman C; Di Ruscio A
    Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33804735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
    Putt KS; Hergenrother PJ
    Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Crystal structure and biochemical activity of the macrodomain from rubella virus p150.
    Stoll GA; Nikolopoulos N; Zhai H; Zhang L; Douse CH; Modis Y
    J Virol; 2024 Feb; 98(2):e0177723. PubMed ID: 38289106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.